Chardan initiated coverage of Alto Neuroscience (ANRO) with a Buy rating and $15 price target The firm views Alto as a diversified play in the depression space. The company has a diversified portfolio of products in Phase 2 trials, with “promising” early evidence to support potential benefits in depressive disorders, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANRO:
- Innovative Biomarker Strategy and Promising Pipeline Drive Buy Rating for Alto Neuroscience
- Innovative Precision Psychiatry and Strong Financials Justify Buy Rating for Alto Neuroscience
- Alto Neuroscience announces results from replication study
- Promising Pipeline and Expert Backing Drive Buy Rating for Alto Neuroscience, Inc.
- Alto Neuroscience: Strategic Pipeline Expansion and Strong Financial Position Justify Buy Rating